(The Hill) — A new poll from the health policy nonprofit KFF found that one in eight adults say they’ve taken a GLP-1 agonist ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...

Lexaria's DehydraTECH-processed Rybelsus ® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide ... Blood samples were taken multiple times during the first ...

Findings from two US trials of efsitora, developed by pharma company Eli Lilly, have been presented at the annual meeting of ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug ... both adults and children. Vaxchora has been available in the US since ...

Novo Nordisk’s stock value surged by over 8% following the drug’s presentation at an investor meeting on March 7, 2024.. The surging interest in a new class of medications known as GLP-1 ...

Thus, semaglutide’s appetite-suppressing effect makes it a useful drug for weight loss and management when used in conjunction with diet and exercise. Obesity in adults ... US are currently on a ...

The maker of a weight loss drug has asked regulators to allow them to expand the use of the medication down to the age of six. It comes as Liraglutide, a drug approved to treat obesity in adults and ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study shows. Liraglutide lowered body ...